The period immediately following a fragility fracture is critical; this is the point where her fracture risk escalates, and decisions made here can shape what follows.^1,2 Join us for this interactive, case-based symposium and hear real-world insights into the management of PMO patients at VHFR from our international panel of experts. Discover how romosozumab, through rapid bone-building ability, stands out as an optimal approach to rapidly reduce fracture risk and, when followed with an antiresorptive, enables long-term prevention of future fractures.^3-5

Complimentary lunch will be provided for symposium attendees.